Impact News +++ EnerSys (ENS) is a Top-Ranked Growth Stock: Should You Buy? (Zacks) +++ ENERSYS Aktie +3,02%

TVARDI Aktie

>TVARDI Aktienkurs

3.582 EUR (Tradegate)

Ask: 3.634 EUR / 4200 Stück

Bid: 3.529 EUR / 4300 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

TVARDI Aktie über LYNX handeln

Intraday

1 Jahr

>TVARDI Performance

1 Woche: +2,8%

1 Monat: -90,1%

3 Monate: -82,6%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>TVARDI Aktie

Name:

TVARDI THERAPEUTICS O.N.

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US1407553072 / A414VY

Symbol/ Ticker:

69C (Frankfurt) / TVRD (NASDAQ)

Kürzel:

FRA:69C, ETR:69C, 69C:GR, NASDAQ:TVRD

Index:

Webseite:

https://tvarditherapeutic..

Profil:

Cara Therapeutics Inc. is a biopharmaceutical comp..
>Volltext..

Marktkapitalisierung:

34.17 Mio. EUR

Unternehmenswert:

-0.28 Mio. EUR

Umsatz:

5.65 Mio. EUR

EBITDA:

-20.14 Mio. EUR

Nettogewinn:

-17.95 Mio. EUR

Gewinn je Aktie:

-13.7 EUR

Schulden:

0.22 Mio. EUR

Liquide Mittel:

17.74 Mio. EUR

Operativer Cashflow:

-27.14 Mio. EUR

Bargeldquote:

3.84

Umsatzwachstum:

-45.59%

Gewinnwachstum:

82.9%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

TVARDI

Letzte Datenerhebung:

14.11.25

>TVARDI Kennzahlen

Aktien/ Unternehmen:

Aktien: 9.38 Mio. St.

Frei handelbar: 65.7%

Leerverk. Aktien: 10.95%

Rückkaufquote: -1.07%

Mitarbeiter: 10

Umsatz/Mitarb.: 0.61 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 235.71%

Bewertung:

KGV: -

KGV lG: -

KUV: 5.29

KBV: 1.23

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -317.54%

Operative Marge: -358.01%

Managementeffizenz:

Gesamtkaprendite: -35.95%

Eigenkaprendite: -93.85%

>TVARDI Peer Group

Es sind 599 Aktien bekannt.

>TVARDI Chart & Kurs - NASDAQ

>TVARDI News

14.11.25 - 16:33	SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered losses in Tvardiand would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson......

13.11.25 - 22:42	Tvardi Therapeutics GAAP EPS of -$0.59 beats by $0.22 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.25 - 22:06

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update (Business Wire)

On track for topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) in H1 2026 Results from healthy volunteer study of its next-generation STAT3 inhibitor, TTI-109, expected in H1 2026 Cash runway sufficient to fund operations into Q4 2026HOUSTON--(BUSINESS WIRE)--#IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat ﬁbrosis-driven diseases, today announced its ﬁnancial and operating results for the third quarter ended September 30, 2025, and provided a business update. Third Quarter 2025 and Recent Highlights: Continued to progress its Phase 2 study of TTI-101 in HCC, with topline data anticipated in the first half of 2026. Announced that the IND for its next-generation STAT3 inhibitor, TTI-109, is in effect and that a healthy volunteer study has been initiated, results of which are anticipated in the first half ...

03.11.25 - 16:21	INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights,......

28.10.25 - 14:33	TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights,......

23.10.25 - 19:06	Faruqi & Faruqi Reminds Tvardi Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 3, 2025 - TVRD (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights,......

15.10.25 - 16:03	TVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights,......

14.10.25 - 19:00	TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals (Zacks)
	Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo....

13.10.25 - 13:54	Fehlschlag bei IPF-Studie: Aktie von Tvardi Therapeutics stürzt um 30 % ab (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

15.08.25 - 01:36	Tvardi Posts Q2 Net Income Turnaround (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

13.06.25 - 03:21	Recently Listed Tvardi Therapeutics Lead Drug Positioned To Drive Broad Improvement, Analyst Sees Over 150% Stock Upside (Benzinga)
	Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026. read more...

22.04.25 - 13:01	XFRA: 69C: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN TVARDI THERAPEUTICS O.N. 69C US1407553072 AB/FROM ONWARDS 22.04.2025 12:54 CET...

16.04.25 - 08:42	XFRA: 69C: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL TVARDI THERAPEUTICS O.N. 69C US1407553072 BAW/UFN...

16.04.25 - 08:01	XFRA: INSTRUMENT_SUSPENSION - US1407553072 (XETRA)
	Instrument ID [23585269] (69C - US1407553072) suspended...

15.04.25 - 16:48	XFRA: ISIN Change (XETRA)
	Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen US1407552082 Cara Therapeutics Inc. 15.04.2025 US1407553072 Cara Therapeutics Inc. 16.04.2025 Tausch 3:1...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wie der Pfaff, so die Gemeinde. - Sprichwort Rußland

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram